Eli Lilly and Company (NYSE: LLY) today announced topline results from the SURMOUNT-5 phase 3b open-label randomized clinical ...

The trial enrolled 751 adults with obesity or overweight conditions and at least one weight-related medical problem ...

Pharmaceutical giants Eli Lilly and Company & Novo Nordisk A/S face challenges in the obesity market despite promising data.

Adults taking Zepbound lost 47% more weight on average than those taking Wegovy, according to clinical trial data from ...

Patients lost an average of 20.2% of their weight with tirzepatide over 72 weeks versus 13.7% with semaglutide.

SURMOUNT-5’s results reflect those of multiple real-world studies, which have found that tirzepatide treatment results in ...

An open- label Phase III trial showed that participants using Zepbound saw 47% greater relative weight loss compared to ...

A new study is shedding light on which of two drugs currently approved by the U.S. Food and Drug Administration for weight ...

Eli Lilly's popular weight-loss drug Zepbound outperformed Danish drugmaker Novo Nordisk's Wegovy in a clinical trial, ...

People who took Zepbound, Eli Lilly’s weight loss drug, shed more pounds than those on Novo Nordisk’s Wegovy in a clinical ...

Over the last two-plus years, as Eli Lilly and Novo Nordisk have battled for their share of the massive weight loss market ...

The bears might point out that Eli Lilly's shares still look too expensive: The company's trailing price-to-earnings (P/E) ...